Leucine

Leucine

SCHEMBL7366609

CC(C)C(N)C(=O)O.CC(C)CC(N)C(=O)O.CC(N)C(=O)O

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.72
SLC1A3 P43003 6/20 0.57
SLC1A2 P43004 6/20 0.57
SLC1A1 P43005 6/20 0.53
GRIK1 P39086 8/20 0.41
GRIK2 Q13002 5/20 0.41
GRM1 Q13255 1/20 0.41
GRM2 Q14416 1/20 0.41
GRIA2 P42262 2/20 0.39
GRIA4 P48058 2/20 0.39
GRIK3 Q13003 2/20 0.39
GRIK5 Q16478 2/20 0.39
GRIA1 P42261 1/20 0.39
RNPEP Q9H4A4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leucine SCHEMBL2553000 1.00 SLC7A5 (0.72) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL4401591 0.96 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
D-Leucine SCHEMBL11768667 0.96 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL17184327 0.96 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL11305893 0.96 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL375261 0.96 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL17184328 0.96 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL466383 0.96 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL466382 0.96 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL28161805 0.96 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP claimed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP claimed
US-20210315915-A1 PHARMACEUTICAL COMPOSITIONS OF RIBAVIRIN GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-10-14 US disclosed
EP-1159294-A1 CARBOHYDRATE EPITOPE MIMIC PEPTIDES AND USES THEREOF Acorda Therapeutics (US) 2001-12-05 EP disclosed
WO-2000050447-A1 CARBOHYDRATE EPITOPE MIMIC PEPTIDES AND USES THEREOF ACORDA THERAPEUTICS (US) 2000-08-31 WO disclosed
WO-1998032878-A1 GENE BASED ASSAY FOR AGENTS WITH POTENTIAL THERAPEUTIC EFFICACY IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND DISORDERS RELATED THERETO THE ROCKEFELLER UNIVERSITY (US) 1998-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210315915-A1 PHARMACEUTICAL COMPOSITIONS OF RIBAVIRIN EIF2AK2, IFNAR1, SARS1 SLC7A5 4425/4885SLC1A3 4830/4885SLC1A2 4850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.